Breakthrough in Treating Autoimmune Diseases: Research Suggests Novel Approach to Hinder MS Progression

Strategic Insights -

Scientists at Sungkyunkwan University have made a significant breakthrough in the treatment of autoimmune diseases, specifically multiple sclerosis (MS). The research, funded by the Ministry of Science & ICT (MSIT), Republic of Korea, has led to the development of a therapeutic vaccine that effectively reduces glycolysis in MS-mediated activated immune cells. This innovative approach has the potential to treat various autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, and systemic lupus erythematosus.

Key Takeaways:

  • The research found that pathogenic autoreactive T cells targeting myelin-derived self-antigens are primary drivers of severe MS progression.
  • The proposed nanovaccine reduces glycolysis in MS-mediated activated immune cells by diminishing GLUT1 expression, leading to the inhibition of Th1 and Th17 cell activation and differentiation.
  • The therapeutic vaccine effectively dampens autoimmune disorders in an MS-imitating experimental autoimmune encephalomyelitis (EAE) mouse model in both early and late chronic conditions.
  • The nanovaccine is composed of epigallocatechin gallate (EGCG) nanoparticles with glycolysis-regulating capabilities co-loaded with myelin-derived autoantigens and the immunosuppressive agent rapamycin.
  • This research has been peer-reviewed and published in the Chemical Engineering Journal.

Statistics:

  • 520 is the issue number of the Chemical Engineering Journal where the research was published.
  • The research was conducted by a team of scientists from Sungkyunkwan University, including Jaeyun Kim, Ngoc Man Phan, Dong Kwang Min, Xin Wang Mo, and Pilseon Im.
  • The research was funded by the Ministry of Science & ICT (MSIT), Republic of Korea.

Sources:

  • Chemical Engineering Journal, 2025:520
  • NewsRx. Studies from Sungkyunkwan University Provide New Data on Multiple Sclerosis (Glycolysis-regulating Polyphenol Nanoparticles Restore Immune Homeostasis and Tolerance In Autoimmune Multiple Sclerosis). Vaccine Weekly. October 15, 2025; p 641
  • Elsevier Science Sa, PO Box 564, 1001 Lausanne, Switzerland (www.elsevier.com)
  • Sungkyunkwan University, School of Chemical Engineering, Suwon 16419, South Korea. (Sungkyunkwan University)